Accepted Manuscript

Therapeutic approaches to control tissue repair and fibrosis: Extracellular matrix as a game changer

Marielle Walraven, Boris Hinz



To appear in:

Received date:	28 December 2017
Revised date:	22 February 2018
Accepted date:	23 February 2018

Please cite this article as: Marielle Walraven, Boris Hinz, Therapeutic approaches to control tissue repair and fibrosis: Extracellular matrix as a game changer. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Matbio(2017), doi:10.1016/j.matbio.2018.02.020

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

THERAPEUTIC APPROACHES TO CONTROL TISSUE REPAIR AND FIBROSIS: EXTRACELLULAR MATRIX AS A GAME CHANGER

Marielle Walraven and Boris Hinz

Laboratory of Tissue Repair and Regeneration, Matrix Dynamics Group, Faculty of Dentistry, University of Toronto, Fitzgerald Building, Room 234, 150 College Street, Toronto, ON M5S 3E2, Canada

Please address all correspondence to: Boris Hinz, PhD, Professor Laboratory of Tissue Repair and Regeneration Matrix Dynamics Group Faculty of Dentistry Fitzgerald Building, Room 234 University of Toronto 150 College Street Toronto, Ontario M5S 3E2, Canada Phone: +1 416-978-8728 FAX: +1 416-978-5956 boris.hinz@utoronto.ca

Disclosures

The authors have approved the final version of this manuscript and have no conflicts of interest to declare.

Abbreviations:

Extracellular matrix (ECM), tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), hyaluronic acid (HA), idiopathic pulmonary fibrosis (IPF), Food and Drug Administration (FDA), basic fibroblast growth factor (bFGF), interferon- γ (IFN- γ), interleukin (IL), platelet derived growth factor (PDGF), bone morphogenetic protein (BMP), phosphatidylinositol 3-kinase (PI3 K)-AKT, focal adhesion kinase (FAK), lysophosphatic acid (LPA), matrix metalloproteases (MMPs), lysyl oxidase (LOX), LOX-like (LOXL), extra domain A (ED-A), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), transforming growth factor β (TGF- β), latent TGF- β binding proteins (LTBP), glycosaminoglycan (GAG), small leucine-rich proteoglycans (SLRPs), plasmin-activation inhibitor-1 (PAI-1), milk fat globule-EGF factor 8 (Mfge8), mesenchymal stem cells (MSCs), insulin-like growth factor (IGF), Transglutaminase (TG).

Download English Version:

https://daneshyari.com/en/article/10157701

Download Persian Version:

https://daneshyari.com/article/10157701

Daneshyari.com